INVICTUS aimed to assess rivaroxaban compared with vitamin K antagonists (VKAs) in patients with rheumatic heart disease related atrial fibrillation. In this touchCARDIO interview, we speak with Professor Ganesan Karthikeyan (All India Institute of Medical Sciences, New Delhi, India) to discuss the INVICTUS rheumatic heart disease research program and what this means for clinical practice.Â
The abstract entitled ‘INVICTUS – Rivaroxaban versus VKA for rheumatic atrial fibrillation’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
Questions:
- What are the aims and design of the INVICTUS rheumatic heart disease research program? (0:25)
- What were the study findings and what is their clinical significance? (1:37)
- What questions remain unanswered and what future studies are planned? (3:04)
Disclosures: Ganesan Karthikeyan has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Atrial Fibrillation here and Cardiovascular Disease here
